Humacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to “Sell”

Humacyte (NASDAQ:HUMA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

HUMA has been the subject of a number of other reports. HC Wainwright cut their price objective on Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday, August 11th. TD Cowen cut their price objective on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Finally, Benchmark lowered their price target on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.64.

Humacyte Price Performance

Humacyte stock opened at $1.88 on Friday. The stock has a market capitalization of $291.63 million, a PE ratio of -4.18 and a beta of 1.90. Humacyte has a 12 month low of $1.15 and a 12 month high of $7.48. The business has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.45. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 3.28.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.94 million. On average, analysts anticipate that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Trading of Humacyte

A number of institutional investors have recently made changes to their positions in the company. Beacon Pointe Advisors LLC boosted its stake in shares of Humacyte by 33.3% in the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock worth $101,000 after acquiring an additional 5,000 shares during the last quarter. Endowment Wealth Management Inc. boosted its stake in Humacyte by 5.1% during the second quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company’s stock worth $229,000 after buying an additional 5,350 shares during the last quarter. Wealth Effects LLC boosted its stake in Humacyte by 5.8% during the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after buying an additional 5,600 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Humacyte by 20.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company’s stock worth $172,000 after buying an additional 5,801 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in Humacyte by 24.1% during the second quarter. ProShare Advisors LLC now owns 31,493 shares of the company’s stock worth $66,000 after buying an additional 6,106 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.